A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus

Trial Profile

A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Lixisenatide; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LixiLan-O
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Jun 2018 Post hoc analysis results from LixiLan-O and LixiLan-L studies were presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Results of a post-hoc analysis presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 09 Dec 2017 Results of an analysis comparing the results of the LixiLan and DUAL clinical development programmes, presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top